Related Experiment Video
Updated: May 20, 2025
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel Therapies
Martina Bedeschi1, Elena Cavassi1, Antonino Romeo2
1Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
Abstract:
Glial-origin brain tumors, particularly glioblastomas (GBMs), are known for their devastating prognosis and are characterized by rapid progression and fatal outcomes. Despite advances in surgical resection, complete removal of the tumor remains unattainable, with residual cells driving recurrence that is resistant to conventional therapies. The GBM tumor microenviroment (TME) significantly impacts tumor progression and treatment response. In this review, we explore the emerging role of purinergic signaling, especially the P2X7 receptor (P2X7R). Due to its unique characteristics, it plays a key role in tumor progression and offers a potential therapeutic strategy for GBM through TME modulation. We discuss also the emerging role of the P2X4 receptor (P2X4R) as a promising therapeutic target. Overall, targeting purinergic signaling offers a potential approach to overcoming current GBM treatment limitations.
Insights
Targeting purinergic signaling, specifically P2X7R and P2X4R, offers a novel therapeutic strategy for glioblastoma (GBM). Modulating the tumor microenvironment via these receptors may overcome limitations in current GBM treatments.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Glioblastomas (GBMs) are aggressive brain tumors with poor prognoses.
- Complete surgical resection is often impossible, leading to recurrence.
- The tumor microenvironment (TME) critically influences GBM progression and treatment resistance.
Purpose of the Study:
- To review the role of purinergic signaling in GBM.
- To highlight the therapeutic potential of P2X7 receptor (P2X7R) and P2X4 receptor (P2X4R) targeting.
- To explore TME modulation as a strategy against GBM.
Main Methods:
- Literature review focusing on purinergic signaling pathways in GBM.
- Analysis of the P2X7R and P2X4R roles in tumor progression and TME.
- Discussion of therapeutic implications for glioblastoma treatment.
Main Results:
- Purinergic signaling, particularly P2X7R, significantly impacts GBM progression.
- P2X7R modulation presents a potential therapeutic avenue by altering the TME.
- P2X4R emerges as another promising target for GBM therapy.
Conclusions:
- Targeting purinergic signaling pathways offers a promising strategy for GBM.
- Modulating the GBM TME via P2X7R and P2X4R could overcome treatment resistance.
- Further research into purinergic signaling inhibitors may lead to improved GBM therapies.
